Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Theranostics in Brain Tumors.
Shooli H, Nemati R, Ahmadzadehfar H, Aboian M, Jafari E, Jokar N, Nabipour I, Dadgar H, Gholamrezanezhad A, Larvie M, Assadi M. Shooli H, et al. Among authors: ahmadzadehfar h. PET Clin. 2021 Jul;16(3):397-418. doi: 10.1016/j.cpet.2021.03.005. PET Clin. 2021. PMID: 34053584 Review.
PSMA Theranostics: Current Status and Future Directions.
Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. Rahbar K, et al. Among authors: ahmadzadehfar h. Mol Imaging. 2018 Jan-Dec;17:1536012118776068. doi: 10.1177/1536012118776068. Mol Imaging. 2018. PMID: 29873291 Free PMC article. Review.
Precision Medicine Approach in Prostate Cancer.
Assadi M, Jokar N, Ghasemi M, Nabipour I, Gholamrezanezhad A, Ahmadzadehfar H. Assadi M, et al. Among authors: ahmadzadehfar h. Curr Pharm Des. 2020;26(31):3783-3798. doi: 10.2174/1381612826666200218104921. Curr Pharm Des. 2020. PMID: 32067601 Review.
Bench-to-Bedside Theranostics in Nuclear Medicine.
Jokar N, Assadi M, Yordanova A, Ahmadzadehfar H. Jokar N, et al. Among authors: ahmadzadehfar h. Curr Pharm Des. 2020;26(31):3804-3811. doi: 10.2174/1381612826666200218104313. Curr Pharm Des. 2020. PMID: 32067609 Review.
Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.
Assadi M, Rezaei S, Jafari E, Rekabpour SJ, Ravanbod MR, Zohrabi F, Amini A, Keshmiri S, Dadgar H, Ahmadzadehfar H. Assadi M, et al. Among authors: ahmadzadehfar h. World J Nucl Med. 2020 Feb 27;19(1):15-20. doi: 10.4103/wjnm.WJNM_20_19. eCollection 2020 Jan-Mar. World J Nucl Med. 2020. PMID: 32190017 Free PMC article.
198 results